{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:29:41Z","timestamp":1791412181848,"version":"4.3.3"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1053\/j.seminhematol.2005.05.005","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T08:58:14Z","timestamp":1131008294000},"page":"S43-S49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"S2","title":["Decitabine in Chronic Leukemias"],"prefix":"10.1053","volume":"42","author":[{"given":"Jean-Pierre J.","family":"Issa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2005.05.005_bib1","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.1988.6.10.1562","article-title":"Regimen-related toxicity in patients undergoing bone marrow transplantation","volume":"6","author":"Bearman","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/0002-9343(77)90152-8","article-title":"Investigation of a new parameter in chronic lymphocytic leukemia","volume":"63","author":"Binet","year":"1977","journal-title":"Am J Med"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1182\/asheducation-2004.1.163","article-title":"Chronic lymphocytic leukemia","author":"Byrd","year":"2004","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","article-title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib6","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia","volume":"87","author":"Cheson","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0037-1963(03)70045-6","article-title":"Advanced-phase chronic myeloid leukemia","volume":"40","author":"Cortes","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/jmg.38.5.285","article-title":"Methylation matters","volume":"38","author":"Costello","year":"2001","journal-title":"J Med Genet"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1046\/j.1365-2141.1998.00540.x","article-title":"Hypermethylation of the M27beta (DXS255) locus in chronic B-cell leukaemia","volume":"100","author":"Crossen","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib10","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/cncr.11184","article-title":"Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias","volume":"97","author":"de Lima","year":"2003","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib11","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib12","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2684::AID-CNCR13>3.0.CO;2-V","article-title":"The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia","volume":"86","author":"Diehl","year":"1999","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib13","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1535-6108(02)00025-9","article-title":"Perspectives on the development of a molecularly targeted agent","volume":"1","author":"Druker","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib15","first-page":"102","article-title":"Fludarabine and cyclophosphamide produces a higher remission rates and longer progression free survival (PFS) than fludarabine (F) alone in first line therapy of advanced chronic lymphocytic leukemia (CLL)","volume":"104","author":"Eichhorst","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib16","first-page":"169","article-title":"Chronic myelogenous leukemia","volume":"13","author":"Faderl","year":"1999","journal-title":"Oncology (Huntingt)"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood.V104.11.475.475","article-title":"Fludarabine and cyclophosphamide produces a higher complete response rate and more durabel remissions than fludarabine in patients with previously untreated CLL","volume":"104","author":"Flinn","year":"2004","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2005.05.005_bib18","first-page":"S32","article-title":"Studies of decitabine with allogeneic progenitor cell transplantation","volume":"11","author":"Giralt","year":"1997","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00062752-200207000-00007","article-title":"Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia","volume":"9","author":"Gorre","year":"2002","journal-title":"Curr Opin Hematol"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib20","first-page":"457","article-title":"Fludarabine monophosphate","volume":"30","author":"Grever","year":"1988","journal-title":"Nouv Rev Fr Hematol"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib21","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.V82.6.1820.1820","article-title":"bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia","volume":"82","author":"Hanada","year":"1993","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib22","doi-asserted-by":"crossref","first-page":"9700","DOI":"10.1073\/pnas.91.21.9700","article-title":"Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma","volume":"91","author":"Herman","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.hoc.2004.03.001","article-title":"Clinical resistance to imatinib","volume":"18","author":"Hochhaus","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib24","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib25","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2003-03-0687","article-title":"Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2\u2032-deoxycytidine (decitabine) in hematopoietic malignancies","volume":"103","author":"Issa","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2005.11.981","article-title":"Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate","author":"Issa","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib27","first-page":"23","article-title":"Cancer statistics, 2002","volume":"52","author":"Jemal","year":"2002","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.semcancer.2003.11.006","article-title":"Targeted therapies in myeloid leukemia","volume":"14","author":"John","year":"2004","journal-title":"Semin Cancer Biol"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib29","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(96)91681-5","article-title":"Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL","volume":"347","author":"Johnson","year":"1996","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib30","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/sj.leu.2400796","article-title":"Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia","volume":"11","author":"Kantarjian","year":"1997","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib31","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood.V99.10.3547","article-title":"Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase","volume":"99","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib32","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/cncr.11543","article-title":"Results of decitabine (5-aza-2\u2032deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib33","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib34","first-page":"2025","article-title":"Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance","volume":"3","author":"Kantharidis","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V74.1.19.19","article-title":"Fludarabine","volume":"74","author":"Keating","year":"1989","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib36","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib37","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11864-001-0038-0","article-title":"Chronic myelogenous leukemia in chronic phase","volume":"2","author":"Kurzrock","year":"2001","journal-title":"Curr Treat Options Oncol"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib38","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S8756-3282(00)00380-X","article-title":"Human Dermo-1 has attributes similar to twist in early bone development","volume":"27","author":"Lee","year":"2000","journal-title":"Bone"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib39","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V98.8.2319","article-title":"Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients","volume":"98","author":"Leporrier","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib40","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/blood-2001-11-0066","article-title":"Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia","volume":"100","author":"Lin","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib41","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/blood-2003-04-1289","article-title":"High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment","volume":"102","author":"Lin","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib42","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.V72.6.2042.2042","article-title":"Hypomethylation of ornithine decarboxylase gene and erb-A1 oncogene in human chronic lymphatic leukemia","volume":"72","author":"Lipsanen","year":"1988","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib43","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1101\/gad.13.17.2207","article-title":"Twist is a potential oncogene that inhibits apoptosis","volume":"13","author":"Maestro","year":"1999","journal-title":"Genes Dev"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib44","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1182\/blood.V95.10.3208","article-title":"Hypermethylation of E-cadherin in leukemia","volume":"95","author":"Melki","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib45","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/0145-2126(85)90123-7","article-title":"Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2\u2032-deoxycytidine","volume":"9","author":"Momparler","year":"1985","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib46","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib47","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1182\/blood.V104.11.962.962","article-title":"Zap70 methylation correlates with Zap70 expression in chronic lymphocytic leukemia","volume":"104","author":"Oscier","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib48","first-page":"1211","article-title":"CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2\u2032deoxycytidine","volume":"11","author":"Otterson","year":"1995","journal-title":"Oncogene"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib49","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1056\/NEJMe030009","article-title":"Imatinib mesylate\u2014The new gold standard for treatment of chronic myeloid leukemia","volume":"348","author":"Peggs","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib50","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood.V64.4.922.922","article-title":"5-Aza-2\u2032-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias","volume":"64","author":"Pinto","year":"1984","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib51","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib52","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib53","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2005.02.196","article-title":"TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia","author":"Raval","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib54","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/sj.bmt.1703028","article-title":"Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant","volume":"27","author":"Ravandi","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3835(02)00288-4","article-title":"Alterations of DNA methylation in hematologic malignancies","volume":"185","author":"Rush","year":"2002","journal-title":"Cancer Lett"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib56","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1158\/0008-5472.CAN-03-2870","article-title":"Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets","volume":"64","author":"Rush","year":"2004","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib57","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A","article-title":"Chronic myelogenous leukemia in nonlymphoid blastic phase","volume":"86","author":"Sacchi","year":"1999","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib58","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-134-7-200104030-00011","article-title":"Changes in DNA methylation in neoplasia","volume":"134","author":"Santini","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib59","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib60","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib61","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib62","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/(SICI)1097-4644(19990201)72:2<167::AID-JCB1>3.0.CO;2-3","article-title":"Identification of DERMO-1 as a member of helix-loop-helix type transcription factors expressed in osteoblastic cells","volume":"72","author":"Tamura","year":"1999","journal-title":"J Cell Biochem"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib63","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/sj.leu.2402891","article-title":"Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML)","volume":"17","author":"Tessema","year":"2003","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib64","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/sj.leu.2401565","article-title":"Chronic myeloid leukemia from basics to bedside","volume":"13","author":"Thijsen","year":"1999","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib65","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1182\/blood.V80.8.2074.bloodjournal8082074","article-title":"Genomic hypomethylation in human chronic lymphocytic leukemia","volume":"80","author":"Wahlfors","year":"1992","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib66","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng1521","article-title":"Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia","volume":"37","author":"Yu","year":"2005","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminhematol.2005.05.005_bib67","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/gcc.1099","article-title":"TCL1 is activated by chromosomal rearrangement or by hypomethylation","volume":"30","author":"Yuille","year":"2001","journal-title":"Genes Chromosomes Cancer"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719630500065X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719630500065X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:16:00Z","timestamp":1758521760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003719630500065X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":67,"alternative-id":["S003719630500065X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2005.05.005","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decitabine in Chronic Leukemias","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2005.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}